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Abstract: Pulmonary hypertension is an important prognostic factor in cardiac surgery associated with increased 
morbidity and mortality. With the aging population and the associated increase severity of illness, the prevalence of pul-
monary hypertension in cardiac surgical patients will increase. In this review, the definition of pulmonary hypertension, 
the mechanisms and its relationship to right ventricular dysfunction will be presented. Finally, pharmacological and non-
pharmacological therapeutic and preventive approaches will be presented. 
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1. DEFINITION OF PULMONARY HYPERTENSION 
  There are several hemodynamic parameters that are used 
in defining pulmonary hypertension (PHT) (Table 1) [1]. 
Several of these definitions have been used in various 
studies. In cardiac surgery, we obtain information on PHT 
before the procedure and this is usually from an awake 
patient. This preoperative information is either acquired 
through preoperative catheterization or, more frequently, 
estimated  via transthoracic echocardiography by using the 
Bernoulli’s equation. In the presence of tricuspid regur-
gitation, as shown in Fig. (1), [2] the simplified Bernoulli’s 
equation will give an estimation of the pressure gradient 
across the tricuspid valve. This pressure gradient is equal to 
the difference between the systolic pressure of the right 
ventricle (RV) and the right atrium (RA). Therefore, 
knowledge (or estimation) of the right atrial pressure allows 
the estimation of the right ventricular systolic pressure. In 
the absence of right ventricular outflow tract obstruction 
(RVOTO) or pulmonic valve stenosis, this value will be an 
estimation of the systolic pulmonary artery pressure (SPAP). 
  Following the induction of general anesthesia, a redu-
ction of both the systemic and the pulmonary artery 
pressures will be observed. Consequently, absolute values of 
SPAP used in defining PHT will tend to underestimate its 
severity. In 2006, we addressed this issue and published a 
study involving 1557 patients who underwent cardiac 
surgery [3]. We first demonstrated that the induction of 
general anesthesia in 32 patients was associated with a 
significant reduction in mean arterial pressure (MAP), mean 
pulmonary artery pressure (MPAP) but the MAP/MPAP 
ratio did not change (Fig. 2). Therefore, this ratio (normal 
value > 4) seems to be a very robust estimator of the severity 
of PHT. To demonstrate the utility of the MAP/MPAP ratio, 
we compared it to the other hemodynamic parameters listed 
in Table 1 in 1439 patients undergoing cardiac surgery after 
the induction of general anesthesia but before cardio-   
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pulmonary bypass (CPB). We observed that the MAP/MPAP 
ratio behaved similarly to the other hemodynamic parameters 
(Fig. 3), and had the highest receiver operating curve value 
to predict hemodynamic complications after cardiac surgery. 
The hemodynamic complications were defined as posto-
perative death or requirement for an intra-aortic balloon 
pump, cardiac arrest and vasoactive support for more than 24 
hours. Finally, using transesophageal echocardiography 
(TEE), we can confirm that the presence of an abnormal 
MAP/MPAP ratio is almost invariably associated with 
abnormal systolic or diastolic cardiac function (Fig. 4) [3]. 
This concept of using the relative instead of absolute value 
of PHT indices is currently used in congenital cardiology   
[4, 5].  
  Finally, PHT is typically classified as capillary, pre-
capillary or post-capillary, depending on the site where the 
cause of PHT is present. The 2003 World Symposium on 
PHT proposed a classification based on 5 groups: 1-Pulmo-
nary arterial hypertension, 2-PHT secondary to left heart 
disease, 3-PHT secondary to lung disease and/or hypoxia, 4-
PHT secondary to thrombotic and/or embolic disease and 5-
A miscellaneous category [6]. In cardiac surgery, it is typi-
cally post-capillary or group 2 because the cause of PHT is 
of cardiac origin and consequently localized after the pulmo-
nary capillary. This is confirmed using pulmonary artery 
catheterization during which the diastolic pulmonary artery 
pressure is equal to the pulmonary artery occlusion pressure 
(PAOP). In a situation where the diastolic pulmonary artery 
pressure (DPAP) is significantly higher than the PAOP in the 
absence of tachycardia, a capillary or pre-capillary cause 
could be sought [1]. 
  In summary, PHT in cardiac surgery should be carefully 
defined. It is generally a post-capillary PHT. In awake 
patients, the absolute values have been used and correlated 
with outcome. However, in patients under general anes-
thesia, the relative value seems to be more appropriate.  
2. PULMONARY HYPERTENSION IN CARDIAC 
SURGERY: MECHANISM AND ETIOLOGY 
  The mechanism of PHT in cardiac surgery is complex 
and can result from several mechanisms acting alone or in 2    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Denault et al. 
Table 1.  Definitions of Pulmonary Hypertension Used in Clinical Research 
Hemodynamic Parameter [1]  Normal Value  Abnormal Value 
Systolic pulmonary artery pressure (SPAP)  15-30 mmHg  > 30 or  40 mmHg 
Mean pulmonary artery pressure (MPAP)  9-16 mmHg  Moderate: > 18 mmHg  
Significant: > 25 mmHg  
Exercise-induced: > 30 mmHg 
Pulmonary vascular resistance (PVR) = (MPAP – PAOP) X 80/CO  60-120 dyn·s·cm
-5 
1.1-1.4 Wood unit 
Mild: > 125 dyn s cm
-5 
Moderate: > 200-300 dyn s cm
-5 
Severe: > 600dyn
 s cm
-5 
Indexed pulmonary vascular resistance (PVRI) = (MPAP – PAOP) X 80/CI  250-340 dyn·s·cm
-5·m
-2  
Pulmonary to systemic vascular resistance index (PVRI/SVRI) X 100%  < 10%   
Trans-pulmonary gradient (MPAP – PAOP)   < 14 mmHg   
Mean pulmonary to systemic pressure ratio (MPAP/MAP) X 100%  < 25%  Moderate: 33-50%  
Severe: > 50% 
Mean systemic to pulmonary pressure ratio (MAP/MPAP) X 100%  > 4  < 4 [3] 
CO: cardiac output, CI: cardiac index, PAOP: pulmonary artery occlusion pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (A) Estimation of right ventricular systolic pressure (systolic Prv or RVSP) using the pressure gradient (PG) obtained from tricuspid 
regurgitation (TR) and right atrial pressure (Pra or RAP). (B) Note that the RVSP is higher than the systolic pulmonary artery pressure (Ppa) 
due to a small gradient across the pulmonic valve (EKG: electrocardiogram, V: velocity). With permission from Denault et al. [2] (Chapter 5, 
p.111). Pulmonary Hypertension in Cardiac Surgery  Current Cardiology Reviews, 2010, Vol. 6, No. 1    3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Change in MAP, MPAP, and the MAP/MPAP ratio after the induction of anesthesia in 32 patients with preoperative pulmonary 
hypertension. No significant change in the MAP/MPAP ratio was observed (*p < 0.05). (MAP: mean arterial pressure, MPAP: mean 
pulmonary artery pressure) [3]. 
 
combination. These mechanisms can be present before the 
operation, secondary for instance from valvular heart 
disease. The cause of PHT can appear after CPB from 
mechanical failure or from the pulmonary reperfusion 
syndrome. Finally, PHT can be present or persist posto-
peratively secondary for instance from/to a mitral or aortic 
patient-prosthesis-mismatch (PPM). Fig. (5) focuses on the 
role of PHT in cardiac surgery [7] based on current literature, 
our research findings and our experience of this population.  
2.1. Review of the Factors Involved in Pulmonary 
Hypertension in Cardiac Surgery 
  The 6 most important causes of PHT in cardiac surgery 
factors are illustrated in Fig. (5).  
1) Left ventricular systolic or diastolic dysfunction and 
mitral or valvular disease either pre- or postoperative are 
the most common causes of PHT in cardiac surgery. 
Aortic PPM through a reduction in coronary reserve 
could also contribute to postoperative PHT [8]. 
2)  During cardiac surgery, the extent of the systemic inflam-
matory response, the pulmonary reperfusion syndrome 
and the need for blood transfusions may exacerbate PHT 
(Fig. 6) [9, 10]. The mechanism of pulmonary damage 
during extracorporeal circulation is thought to be mainly 
triggered by 1) release of cytokines [11] through 
endotoxin production, 2) complement activation and 3) 
ischemia reperfusion injury [12, 13]. This leads to the 
production of free radicals, endothelin and prostacyclin 
derivatives with nitric oxide inhibition [12]. 
3)  The administration of protamine can induce catastrophic 
pulmonary vasoconstriction in up to 1.8% of patients 
[14]. Protamine can also activate complement and, when 
given at the end of CPB, can induce PHT associated with 
adverse hemodynamic responses ranging from minor 
perturbations to cardiovascular collapse. Three types 
have been described: systemic hypotension, anaphy-
lactoid reaction and catastrophic PHT [15]. The mecha-
nism of PHT with protamine is thought to occur through 
an imbalance of vasoconstrictors and vasodilators which 
leads a reduction in the release of nitric oxide (NO) from 
the pulmonary vasculature [15].  
4) Mitral PPM is another recently described cause of 
residual postoperative PHT. Magne et al.[16] studied 929 
patients who underwent mitral valve replacement (MVR) 
and followed them up for 15 years. Mitral valve PPM 
was defined as not clinically significant if > 1.2 cm/m, 
as moderate if > 0.9 and 1.2 cm/m, and as severe if  
0.9 cm/m. The prevalence of moderate PPM was 69% 
and that of severe PPM was 9%. Severe PPM was found 
to be associated with residual PHT and a 3-fold increase 
in postoperative mortality after adjustment for other risk 
factors. This new and relevant information is currently 
absent from the majority of the studies dealing with 
predictors of survival in mitral valvular surgery.  
5)  Hypoxia, hypercarbia and pulmonary embolism are other 
causes of PHT. They can appear before, during or after 
CPB. For instance, PHT can cause RV dysfunction, 
which will lead to an increase in right atrial pressure. 
This can lead to the opening of a patent foramen ovale 
(PFO), which is present in 20-30% of the general 
population [17]. The consequence of the opening of a 
PFO would be a right-to-left shunt. This would increase 
the severity of hypoxia and lead to an exacerbation of 
PHT. Pulmonary vessels constrict with hypoxia (Euler-
Liljestrand reflex) and relax in the presence of hyperoxia 4    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Denault et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Relationship between the estimated probability of hemodynamic complications and variables used in the evaluation of pulmonary 
hypertension: (A) systolic pulmonary artery pressure (SPAP), (B) MPAP, (C) PVRI, (D) the ratio of SVRI to PVRI, (E) the MAP/MPAP 
ratio, and (F) the transpulmonary gradient defined as MPAP minus pulmonary artery occlusion pressure (PAOP). For easier comparison, the 
scale of the x axis of the SVRI/PVRI and the MAP/MPAP are inverted. (n = number of patients). (MAP: mean arterial pressure, MPAP: mean 
pulmonary artery pressure, PVRI: indexed pulmonary vascular resistance, SVRI: indexed systemic vascular resistance) [3]. Pulmonary Hypertension in Cardiac Surgery  Current Cardiology Reviews, 2010, Vol. 6, No. 1    5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Hemodynamic and transesophageal echocardiographic evaluation of a 46-year-old woman scheduled for aortic valve surgery. 
Despite a normal pulmonary artery pressure of 34/16 mmHg and PVRI at 286 dyn·s·cm-5·m-2, this patient had an abnormal right ventricular 
diastolic filling pressure waveform characterized by a rapid upstroke (A) and reduced systolic (S) to diastolic (D) pulmonary (B) and hepatic 
(C) venous flow consistent with left and right ventricular diastolic dysfunction. In addition, a dilated right atrium and ventricle were present 
without significant tricuspid regurgitation in a mid-esophageal right ventricular view (D). The MAP/MPAP ratio was 65/23 or 2.8. (CI: 
cardiac index, Pa: arterial pressure, PCWP: pulmonary capillary wedge pressure, Ppa: pulmonary arterial pressure, Pra: right atrial pressure, 
Prv: right ventricular pressure, PVRI: pulmonary vascular resistance index, RA: right atrium, RV: right ventricle, SVRI: systemic vascular 
resistance index) [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). The most common mechanisms that could induce pulmonary hypertension in cardiac surgery. (See Section 2.1 for details) (PFO: 
patent foramen ovale).  6    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Denault et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Unexpected pulmonary hypertension upon weaning from cardiopulmonary bypass (CPB) in a 76-year-old woman after aortic valve 
replacement (AVR). The CPB duration was 71 minutes. A significant increase in pulmonary arterial pressure in relation to the systemic 
arterial pressure was observed as the patient was weaned from CPB. No mechanical causes were found. 
 
  [18]. Hypercarbia can occur particularly if acute lung 
injury occurs during or after the procedure. The increase 
in PCO2 will increase PHT through vasoconstriction. 
Finally, although pulmonary embolism is rare in the 
immediate postoperative period, they can occur 
particularly in patients with predisposing factors (Fig. 7). 
6) Lung volumes have a differential effect on intra- and 
extra-alveolar vessels, which accounts for the unique U-
shaped relationship between lung volume and pulmonary 
vascular resistance (PVR). PVR is minimal at functional 
residual capacity and increased at large and small lung 
volumes (Fig. 8). Clinically, this may be observed when 
hyperinflation of the lungs greatly increases PVR [18]. 
Application of high levels of positive end-expiratory 
pressure (PEEP) may narrow the capillaries in the well 
ventilated lung areas and divert flow to less well 
ventilated or non-ventilated areas, potentially leading to 
hypoxia. An increase in cardiac output distends open 
vessels and may recruit previously closed vessels, 
decreasing PVR. Regional blood flow to lung is also 
influenced by gravity; pulmonary blood flow is greater in 
the dependant areas of the lung. In addition, increase in 
intrathoracic pressure will be transmitted to the 
surrounding cardiac pressure and contribute to elevate 
pulmonary artery pressure. Mechanical compression of 
pulmonary vessels can be caused by hemothoraces or 
tension pneumothoraces.  
    Finally, multiple molecular pathways are important for 
the regulation of PVR. These include the nitric oxide, prosta-
cyclin, endothelin-1 and serotonin pathways [19]. Nitric 
oxide and prostacyclin are endogenous vasodilators pro-
duced in the pulmonary vascular endothelium. Endothelin-1 
is an endogenous vasoconstrictor peptide secreted by the 
vascular endothelium and plays a role in pulmonary 
vasoconstriction and vascular smooth muscle proliferation 
[20]. The neurotransmitter serotonin and the serotonin recep-
tor transporter have also been implicated in the regulation of 
pulmonary vascular tone. An imbalance in these pathways 
may lead to vasoconstriction and vascular remodelling, 
potentially leading to progressive pulmonary vascular 
disease. 
  The most dreadful consequence of PHT is the increase in 
RV afterload and RV dysfunction; this issue will be 
addressed here. 
2.2 Right Ventricular Dysfunction 
  There is growing evidence that morbidity and mortality 
associated with PHT are dependent on RV adaptation to 
disease rather than on the absolute value of pulmonary 
arterial pressure [21-25]. In studies addressing hemodynamic 
variables and survival in idiopathic pulmonary arterial 
hypertension, high mean right atrial pressures and low 
cardiac output (CO) were consistently associated with poorer 
survival when contrasted with pulmonary arterial pressure Pulmonary Hypertension in Cardiac Surgery  Current Cardiology Reviews, 2010, Vol. 6, No. 1    7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Pulmonary embolism immediately after coronary revascularization. This patient was hospitalized and waiting for more than a week 
before the procedure could take place. At the end of the procedure while she was transferred in her bed, she became hemodynamically 
unstable. Immediate transesophageal echocardiographic exam was performed and showed the appearance of a clot in the right pulmonary 
artery (A-B). She was brought back to the operating room for urgent embolectomy and a clot was removed (C). She was discharged from the 
hospital in good condition. (Ao: aorta, RPA: right pulmonar artery, SCV: subclavian vein, SVC: superior vena cava) (Courtesy of Dr. David 
Braco and Dr. Nicolas Noiseux). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Relationship between lung volume and pulmonary vascular resistance (PVR). PVR is minimal at functional residual capacity (FRC) 
and increased at large or total lung capacity (TLC) and small lung volumes residual volume (RV) decreases. The differential effect on intra- 
and extra-alveolar vessels accounts for the U-shaped relationship of PVR and lung volume. (Adapted from Fischer et al. [18]).  8    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Denault et al. 
alone, which was only moderately related to outcome [21, 
26].  
  The importance of RV function in cardiac surgery has 
been demonstrated in a variety of clinical settings such as 
high risk coronary or valvular heart disease, congenital heart 
disease, heart transplantation, in patients requiring mecha-
nical assist devices and in the unstable postoperative patient 
(Table 2) [25]. However, most of the evidence that supports 
the importance of RV function is based on retrospective or 
small prospective studies. To date, parameters of RV func-
tion have not been included in large scale risk stratification 
models and therefore their incremental value to the Parson-
net Score or the EuroSCORE have not been well established 
[27-30]. A recent panel from the National Institute of Health 
(NIH) has stressed the importance of research in the 
understanding of RV failure [24].  
2.2.1. Before the Procedure 
  In patients presenting with severe aortic stenosis, Boldt et 
al. have demonstrated that preoperative RV dysfunction was 
associated with a greater requirement of postoperative 
inotropic support [31]. In a retrospective study of patients 
undergoing mitral and mitral-aortic valvular surgery, Pinzani 
et al. demonstrated that preoperative RV failure was asso-
ciated with perioperative mortality. In this same study, 
postoperative RV failure was the most important inde-
pendent predictor of late survival [32]. In a small prospective 
study of 14 patients with severe non-ischemic mitral 
regurgitation and high risk descriptors (LV ejection (LVEF) 
 45% or RV ejection fraction (RVEF)  20%), Wencker et 
al. found that preoperative RVEF 20% predicted late 
postoperative deaths [33]. In patients under-going coronary 
artery surgery, Maslow et al. [34] showed than RV dysfunc-
tion defined by a RV fractional area change (RVFAC) less 
than 35% in the context of severe LV systolic dysfunction 
(LVEF   25%) and non-emergent coronary artery bypass 
surgery was associated with an increased risk of posto-
perative morbidity and mortality. In their retrospective study 
(n=41), patients with RV dysfunction had a higher preva-
lence of diabetes mellitus and renal disease as well as a 
higher incidence of postoperative inotropic or mechanical 
support, longer intensive care unit and hospital stay and a 
decreased short term and long term survival.  
  To further assess the value of RV function relative/-
compared to other validated risk factors in open valvular 
heart surgery, we recently published our experience related 
to 50 patients undergoing valvular surgery [35]. We 
confirmed that, in patients with a RV myocardial perfor-
mance index (RVMPI) above 50% (n=20), the number of 
patients with DSB (difficult separation from bypass) (16/20 
(80%)  vs. 6/30 (20%), p<0.0001) and the end-point of 
mortality of postoperative heart failure (14/20 (74%) vs. 3/30 
(10%),  p<0.0001) were significantly higher. On a multi-
variate analysis, among all other demographic, hemo-
dynamic and echocardiographic variables, the RVMPI was 
the only independent predictor of heart failure and mortality 
(OR: 25.20, 95%; CI 5.24-121.15, p<0.0001).  
2.2.2. After the Procedure 
  The presence of RV failure after CPB is associated with a 
mortality rate ranging from 44% to 86% [36]. The incidence 
of post-cardiotomy acute refractory RV failure ranges from 
0.04 to 0.1%. Acute refractory RV failure has also been 
reported in 2-3% patients after a heart transplant and in 
almost 20-30% patients who receive a left ventricular assist 
device support with a reported initial salvage rate is only 25-
30% [10]. 
3. IMPORTANCE AND IMPACT OF PULMONARY 
HYPERTENSION IN CARDIAC SURGERY 
  PHT present before any cardiac procedure is associated 
with increased morbidity and mortality [27,37-40]. However, 
the presence of PHT is not routinely reported to the surgeon. 
This can be explained by the use of preoperative risk 
stratification models in cardiac surgery, in which only 4/19 
models used PHT as a risk factor [41]. Interestingly, the 
EuroSCORE model, which had the highest discriminatory, is 
one of the models in which PHT is included. In a study that 
included 4351 CABG patients operated in Sweden, the 
receiver operating characteristics (ROC) of EuroSCORE 
model was 0.86 and 0.75 for the 30-day and one year 
mortality, respectively. 
  Using our database in 1999, the mean preoperative 
systolic pulmonary artery pressure (SPAP) was 31±10 
mmHg. Elevated SPAP above 30 mmHg were present 
mostly in mitral valve replacement (n=80, 40±14 mmHg), 
followed by combined CABG and valve (n=126, 36±13 
mmHg), multiple valves (n=60, 36±16 mmHg) and heart 
transplantation (n=6, 36±14 mmHg). A total of 605 patients 
(42%) presented with elevated SPAP defined as above 30 
mmHg. If we select patients with more severe PHT using a 
MAP/MPAP ratio < 2, there were only 16 patients, all 
experienced difficult separation from CPB, 3 died (18.7% 
mortality) and half required vasoactive support for more than 
24 hours after the procedure.  
  For this reason, it is relatively clear that the presence of 
PHT before the operation or appearing during or after it will 
have an impact on survival and mostly through its effect on 
right ventricular function. The next question is: how can we 
prevent or treat PHT and its consequence, RV failure? 
4. PHARMACOLOGIC AND NON-PHARMACO-
LOGIC APPROACHES IN THE TREATMENT AND 
PREVENTION OF PULMONARY HYPERTENSION 
IN CARDIAC SURGERY 
  The choice of the appropriate therapy should be based on 
evidence-based medicine. A MEDLINE search was perfor-
med using the key words ‘randomized controlled trial’ 
(RCT), ‘humans’, ‘adults’, ‘English’ and ‘PHT’. Articles 
related to cardiac surgery were then selected and classified 
according to the levels of evidence proposed by Sackett [42] 
for evidence-based medical practice. Using this strategy, a 
total of 10 articles were retrieved. In addition, the Consort 
statement group has developed guidelines to assess the 
quality of randomized controlled clinical trials [43]. These 
studies are summarized in Table 3. 
4.1. Treatment of Pulmonary Hypertension 
4.1.1.Pharmacological 
  The agents studied were: inhaled prostacyclin (PGI2), 
nitric oxide (NO) and intravenous vasodilators such as Pulmonary Hypertension in Cardiac Surgery  Current Cardiology Reviews, 2010, Vol. 6, No. 1    9 
prostacyclin E1 (PGE1), nitroglycerin (NTG), nitroprusside 
(NTP), milrinone, enoximone and dobutamine. One large 
RCT compared heparinise to protamine and explored as a 
secondary end-point the prevention of PHT from protamine 
administration [44]. Most of the studies reviewed included a 
small number of patients and their primary end-points were 
hemodynamic changes.  
  In the most recent trial, Fattouch et al. [45] studied 
patients with PHT (n=58) undergoing MVR for mitral 
stenosis. Inhaled PGI2 (iPGI2) and iNO were compared to 
conventional intravenous vasodilators. The inhaled drugs 
were given just before the end of CPB. Significant 
reductions in PHT indices as well as increase in cardiac 
output (CO) and in RV ejection fraction were observed in 
both inhaled groups compared to conventional treatment. In 
addition, in both inhaled groups, separation from CPB was 
easier, the amount of vasoactive drugs administered was 
smaller and the duration of stay in the ICU and hospital was 
shorter. The same group also compared the same three 
strategies in the treatment of PHT after MVR upon arrival in 
the intensive care unit (ICU) [46]. Inhalation of PGI2 was 
associated with a reduction in PVR and an increase in stroke 
volume. Inhaled NO reduced PVR but did not increase 
Table 2.  Prognostic Value of Right Ventricular Function in Cardiac Surgery (Selected Studies)  
Study  Population  Study Design  RV Dysfunction  Results 
Reitchert et al. 
[65] 
Unstable post-operative 
patients 
Prospective 
n=60  
RVFAC < 35%  RV dysfunction associated with high mortality 
rates 
Pinzani et al. [32]  Mitral and combined 
mitro-aortic surgery  
Retrospective  
n=382 
Clinical definition 
 
Post-operative RV failure is the strongest predictor 
of postoperative mortality  
Cullen et al. [66]  Tetralogy of Fallot   Prospective 
n=35  
Restrictive RV 
physiology  
Restrictive physiology predicts longer intensive 
care unit stay post repair and lower cardiac output  
Gatzoulis et al. 
[67] 
Tetralogy of Fallot  Prospective  
n=41  
Restrictive RV 
physiology  
Restrictive physiology predicts smaller RV and 
better exercise tolerance  
Kromos et al. [68]  LVAD and RV failure   Retrospective  
n=31 
Clinical mean RVEF 
= 11.8% 
Preoperative clinical factors such as fever, 
pulmonary edema, and intraoperative blood 
transfusions were associated with RVAD need 
Hosenpud et al. 
[69] 
Heart Transplantation   Retrospective 
International Society for 
Heart & Lung 
transplantation n=69,205 
RV failure 
associated with 
circulatory failure  
RV failure accounts for up to 20% of early deaths 
Oehiai et al. [70]  LVAD   Retrospective  
n=245  
RV failure requiring 
RVAD  
23 patients (9%) required RVAD. The need for 
circulatory support, female gender, and non-
ischemic etiology were predictors of RVAD need.  
Maslow et al. [34]   CAD undergoing 
coronary bypass surgery 
with LVEF < 25% 
Retrospective  
n=41 
RVFAC < 35%  RV dysfunction is associated with decreased long 
term survival  
Therrien et al. 
[71] 
Tetralogy of Fallot   Prospective   
n=17  
RV remodeling   Severe RV dilatation (RVEDV  >170 ml/m2 or 
RVESV  >85 ml/m2) associated with incomplete 
RV remodeling  
Webb et al. [72, 
73]  
Atrial septal defect   Retrospective series   RV remodeling   Older age at repair and abnormal RV myocardial 
relaxation were associated with incomplete RV 
remodeling  
Denault et al. [74]  Patients undergoing 
bypass surgery  
Retrospective and 
prospective 
n=800 
Dynamic 
obstruction of 
RVOT  
(Gd > 25 mmHg) 
Incidence: 4%, dynamic obstruction of RVOT was 
associated with a higher incidence of difficult 
weaning from bypass 
Haddad et al.[35]  High risk valvular 
surgery  
Prospective  
n=50 
RVFAC < 32% or  
RVMPI > 0.50  
Preoperative RV dysfunction was associated with 
a higher incidence of post-operative circulatory 
failure  
CAD: coronary artery disease, Gd: gradient, LV: left ventricular, LVAD: left ventricular assist device, RV: right ventricular, RVAD: right ventricular assist device, RVES: right 
ventricular end-systolic volume, RVED: right ventricular end-diastolic volume, RVEF: right ventricular ejection fraction, RVFAC: right ventricular fractional area change, RVMPI: 
right ventricular myocardial performance index, RVOT: right ventricular outflow tract obstruction. Based on [25]. 10    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Denault et al. 
stroke volume, and NTP was associated with a reduction in 
systemic arterial pressure and systemic vascular resistance. 
  The administration of protamine can be associated with 
severe PHT followed by RV failure. This condition requires 
immediate treatment. In a study of CABG patients (n=3800), 
Ocal et al. [14] compared two therapeutic approaches in the 
treatment of the protamine reaction observed in 68 patients 
(1.8%). One group received iPGI2 and the other intravenous 
NTG in addition to standard vasoactive agents. The iPGI2 
group showed improved hemodynamics and only 14 patients 
(39%) had to return on CPB compared to all 30 patients 
(100%) in the NTG group. A tendency for shorter length of 
stay in the ICU and reduced mortality was observed in the 
iPGI2 group, but the numbers were too small to be 
statistically significant.  
  To avoid protamine reaction, heparinise I, a heparin 
degrading enzyme, was compared in a multicentered 
randomized controlled trial [44]. However, the results of the 
trial were negative and heparinise I was not associated with 
any reduction in the intervention to treat PHT or any 
reduction in bleeding.  
 Solina  et al. explore the dose-responsiveness of iNO 
given on termination of CPB at 10, 20, 30 and 40 ppm 
compared to intravenous milrinone [47]. Nitric oxide was 
associated with a reduction in PVR with a maximum dose of 
10 ppm. No significant difference in reduction of PVR or 
inotropic requirement was observed compared to milrinone. 
The same authors compared NO 20 ppm and 40 ppm to 
milrinone in patients with PVR above 125 after cardiac 
surgery [48]. The drugs were started after CPB and for 24 
Table 3.  Randomized Controlled Trial in the Treatment of Pulmonary Hypertension in Adult Cardiac Surgery 
  Author  Country  Date  Agents Used  Design  N  Inclusion criteria  Primary End-
Point 
Level of 
Evidence 
1  Fattouch et 
al. [45] 
Italy 2006  iPGI2 vs iNO vs 
intravenous 
vasodilators 
RCT 
Unicenter 
58  MVR + PHT 
before the end of 
CPB 
Hemodynamic A1b 
2  Ocal et al. 
[14] 
Turkey 2005  iPGI2  vs NTG  RCT 
Multicenter 
68  CABG with 
protamine 
reaction after CPB 
Hemodynamic A1b 
3  Stafford et al. 
[44] 
USA NC  2005  Heparinase vs 
protamine 
Non-
inferiority 
clinical trial 
design 
Multicenter 
167  CABG on + off 
pump after CPB 
Bleeding A1b 
4  Fattouch et 
al. [46] 
Italy 2005  iPGI2 vs iNO vs 
intravenous 
vasodilators 
RCT 
Unicenter 
58  MVR + PHT in 
the intensive care 
unit 
Hemodynamic A1b 
5  Hache et al. 
[53] 
Canada 2003  iPGI2 vs 
placebo 
RCT 
Unicenter 
20  PHT before CPB  Hemodynamic  A1b 
6  Solina et al. 
[47] 
USA 2001 iNO vs 
milrinone 
RCT 
Unicenter 
62  PHT after surgery  Hemodynamic B 
7  Feneck et al. 
[49] 
UK 2001  Milrinone vs 
dobutamine 
RCT 
Multicenter 
120  CO < 2 L/min/m 
et PAOP > 10 
mmHg after 
cardiac surgery 
Hemodynamic A1b 
8  Solina et al. 
[48] 
USA 2000 iNO vs 
milrinone 
RCT 
Unicenter 
45  PHT after surgery  Hemodynamic A1b 
9  Schmid et al. 
[50] 
Switzerland 1999  iNO vs NTG vs 
PGE1 
Crossover 
Unicenter 
14  PHT after surgery  Hemodynamic B 
10  Hachenberg 
et al. [51] 
Germany 1997  Enoximone vs 
dobutamine+N
TG 
RCT 
Unicenter 
20  HTP in MVR 
before and after 
surgery 
Hemodynamic A1b 
CABG: coronary artery bypass graft, CO: cardiac output, CPB: cardiopulmonary bypass, iNO: inhaled nitric oxide, iPGI2: inhaled prostacyclin, MVR: mitral valve replacement, NO: 
nitric oxide, NTG: nitroglycerin, OR: operating room, PAOP: pulmonary artery occlusion pressure, PGE1: prostaglandin E1, PGI2: prostacyclin, PHT: pulmonary hypertension, 
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hours in the intensive care unit. Higher systemic arterial 
pressure was observed in the 20 ppm group and higher 
RVEF were obtained in the 40 ppm NO group. The milri-
none group required significantly more phenylephrine and 
tended to have higher heart rate than either of the NO groups 
in the ICU.  
  In patients with CO below 2 L/min/m and PAOP > 10 
mmHg, Feneck compared milrinone to dobutamine in 120 
patients [49]. In a subset of patients with PHT defined as 
(PVR >200 dyne sec cm5; MPAP > 25 mmHg), milrinone 
had a similar effect to dobutamine on the reduction of PVR 
and increase in cardiac index (CI). The PAOP and systemic 
vascular resistance (SVR) were more reduced by milrinone.  
 Schmid  et al. [50] compared three approaches (iNO vs 
PGE1 vs NTG) in a crossover study; these were used to treat 
PHT after cardiac surgery in 14 patients. Only stable patients 
were included in the study, which limits the application of 
the results. Inhaled NO decreased PVR without reducing 
SVR, did not change coronary perfusion pressure of the right 
coronary pressure and increased oxygen transport. 
 Finally,  Hachenberger  et al. [51] explored the role of 
enoximone compared to NTG and dobutamine, given after 
induction of anesthesia and then restarted before the end of 
CPB. Only enoximone was associated with a decrease in 
MPAP and PVR. 
  In our practice at the Montreal Heart Institute, we 
regularly use iPGI2 [52, 53] and inhaled milrinone [54, 55] in 
the presence of pulmonary hypertension and RV dysfunction 
before and after cardiac surgery. Inhaled NO and oral 
sildenafil are used in refractory cases in the ICU.  
4.1.2. Non-Pharmacological Approach 
  The non-pharmacological approach to the treatment of 
PHT will be directed to the cause or the consequence of 
PHT, as illustrated in Fig. (5). In the presence of PHT secon-
dary to LV failure, intra-aortic balloon counterpulsation will 
facilitate recovery of LV dysfunction. If prosthetic valve 
dysfunction is present after CPB, then return on CPB and 
correction of the problem will be the treatment of choice. 
The correction of hypoxia, hypercapnia and surgical 
thrombo-embolectomy (when surgically indicated) can help 
control PHT. In patients with elevated intrathoracic pressure 
from accumulated air or blood, chest drainage will be the 
solution. However, in some patients undergoing long 
procedures and long CPB duration, chest closure can be 
associated with hemodynamic instability. This is a sort of 
“thoracic compartment” syndrome. In these situations, the 
chest temporarily can be left open to reduce the surrounding 
pressures. Finally, pulmonary artery balloon pump, RV assist 
device (RVAD) or cavopulmonary diversion have been 
described as potential treatments for severe RV dysfunction 
[10].  
4.2. Treatment of Right Ventricular Failure 
  We summarize our approach to the treatment of RV 
failure in Fig. (9). Right ventricular function is evaluated 
visually, using the RV pressure waveform and TEE. Once 
RVOTO is ruled out, the etiology of RV systolic dysfunction 
is divided in two categories. If ischemia is suspected to 
contribute to RV failure, then both the medical and the 
surgical treatment will be oriented toward the promotion of 
RV perfusion. In a non-ischemic etiology is suspected, the 
medical and surgical treatment will be oriented toward an 
increase in contractility (inotropes) and a reduction in RV 
afterload (iNO, iPGI2, inhaled milrinone).  
5. PREVENTION OF PULMONARY HYPERTENSION 
5.1. Pharmacological Approach 
  The prevention of PHT and its consequences could repre-
sent a promising strategy to prevent RV failure. However, 
very few studies have addressed this issue. One of the 
potential targets could be the prevention of the pulmonary 
reperfusion syndrome. In that regard, our group has 
demonstrated in an animal model that iPGI2 [56] and inhaled 
milrinone [54] could prevent endothelial dysfunction 
induced by CPB. Hache et al. [53] conducted a pilot RCT in 
patients with preoperative PHT and demonstrated that iPGI2 
was superior to placebo in reducing PHT. Furthermore, in 
patients who received iPGI2, the amount of vasoactive 
support was reduced.  
  We have completed a randomized controlled trial on the 
use of inhaled milrinone administered before CPB in 21 
patients. There were 8 males and 13 females of a mean age 
of 70±6.3 years and a mean Parsonnet Score of 32±9. All 
procedures were valvular surgeries, 14 of which were 
complex surgeries and 5 reoperations. Mean systolic pulmo-
nary artery pressures (SPAP) were reduced in the inhaled 
milrinone group from 66±20 mmHg (pre-CPB) to 46±20 
mmHg (after CPB) (p<0.001). No changes in SPAP were 
observed in the control group and no differences in systemic 
arterial pressure between the groups were observed. We also 
published our preliminary experience in the use of inhaled 
milrinone involving 70 high risk patients (Parsonnet Score of 
27±14) [27, 55]. Compared with a control group with similar 
baseline characteristics, we observed that the administration 
of inhaled milrinone prior to CPB (n=30) was associated 
with a lesser rate of re-initiation of CPB (9 vs 1; p=0.021) in 
this very high risk group. We also observed postoperatively 
lower pulmonary artery pressures in the pre-CPB group. 
Further studies will be required to determine the efficacy of 
this approach. 
5.2. Non-Pharmacological Approach 
  The selection of the type and size of an aortic prosthetic 
valve could be a very important strategy, because it has been 
shown that, if the effective orifice area (EOA) of the aortic 
valve is too small in relation to body size, the so-called PPM, 
the intraoperative and long-term mortality, is increased [57-
64]. Hence, anticipatory strategies aiming at the prevention 
of PPM, such as the implantation of a better performing 
prosthesis (i.e. stentless bioprosthesis, new generation 
bileaflet mechanical valve, new generation supra-annular 
stented bioprosthetic valve) or the enlargement of the aortic 
root to accommodate a larger prosthesis could contribute to 
reduce PHT after cardiac surgery and facilitate the separation 
from CPB. On the other hand, some of the alternative 
options that can be used to prevent PPM are complex and 
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the surgical procedure and thus CPB time. As a consequence, 
in some cases, the drawbacks of using alternative procedures 
may overcome the benefits of avoiding PPM. It is therefore 
essential to establish accurate criteria to better assess the 
risk-benefit ratio with respect to the prevention of PPM. For 
mitral valve PPM, the best way would be to repair rather 
than replace the mitral valve. However, mitral valve repair 
cannot be provided to a significant number of patients and 
the options are more limited than for aortic valve replace-
ment [16]. 
CONCLUSION 
  In summary, PHT in cardiac surgery is an important 
variable in cardiac surgery. It should be diagnosed before 
cardiac surgery and the impact of PHT on RV function 
determined. Future trials should address the role of pre-
emptive reduction in the severity of PHT before cardiac 
surgery and their impact on post-operative outcome.  
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